Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$1.79
EPS est.
$1.70
EPS surprise
+5.11%
1-day move
-8.37%
Krystal Biotech reported a positive surprise on EPS, but the stock fell by 8.37% following the earnings release. Investors may be reacting to the lack of revenue information and the absence of guidance, which can create uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.79 | N/A | +5.11% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Krystal Biotech, Inc. (KRYS) is a biotechnology company focused on developing gene therapies for skin diseases. With a market cap of $10 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to evolve.
Last quarter
In Q1 2026, Krystal Biotech reported an EPS of $1.83, surpassing expectations by 26.21%. The stock reacted positively, increasing by 7.86% the following day.
EPS beat streak
4Q
EPS beat rate
75%
Avg EPS surprise
+23.73%
Avg 1-day reaction
-1.88%
Investors are anticipating another strong performance from Krystal Biotech, especially after the recent earnings beat. However, without analyst estimates, expectations are uncertain.
Bull case
If the company continues its trend of beating EPS estimates, it could see significant stock price appreciation, reflecting strong investor confidence.
Bear case
Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price, similar to past performance.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
The EPS figure will be crucial in determining if the company continues its trend of beating expectations and maintaining investor confidence.
Q2
How is revenue expected to grow in the upcoming quarter?
Understanding revenue growth will provide insight into the company's market position and future potential, which is essential for long-term investors.
—
Est. EPS
$0.60
Est. Rev
$13.8B
Impl. Move
±8.2%
Why consensus could be wrong
The market may be underestimating the potential for Krystal Biotech to exceed EPS expectations due to its recent strong performance.
Supporting evidence
The company has a 75% EPS beat rate over the last eight quarters, indicating a strong track record.
The stock reacted positively to recent earnings surprises, suggesting that investor sentiment is strong.
Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger surprise.
Key risk
If the EPS comes in above $2.00, it could challenge the current cautious sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will be closely watched as it could either reinforce the company's growth trajectory or signal potential challenges ahead.
Bull confirmed if
An EPS of $2.00 or higher would confirm the bull case, indicating strong profitability.
Bear confirmed if
An EPS below $1.50 would support the bear case, suggesting potential issues with growth or profitability.
What the market is pricing for the move.
Implied Move
±3.35%
Historical Avg
±8.0%
The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings report.
Options are pricing ±3.3% while KRYS has averaged ±8.0% over the last 8 prints — setup is pricing cheap.
ATM IV
0.4%
30d HV
38.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options pricing cheap in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Krystal Biotech beats expectations, history suggests a potential stock increase of around 2.6%, confirming positive market sentiment.
In line / cautious
If results are in line with past performance, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a significant drop, with historical patterns indicating an average decline of around 14.05%.
The lines on the call that would change the story.